| CNS | Central Nervous System |
| MSCs | Mesenchymal Stem Cells |
| EVs | Extracellular Vesicles |
| ROS | Reactive Oxygen Species |
| ECM | Extracellular Matrix |
| DFU | Diabetic Foot Ulcers |
| VLU | Venous Leg Ulcers |
| HOCl | Hypochlorous Acid |
| DAMPs | Damage-Associated Molecular Patterns |
| SA-EVs | Senescence-Associated EVs |
| TGF-β | Transforming Growth Factor-β |
| CTGF | Connective Tissue Growth Factor |
| IDO | Indoleamine 2,3-dioxygenase |
| FDA | U.S. Food and Drug Administration |
| EMA | European Medicines Agency |
| ATMPs | Advanced Therapy Medicinal Products |
| MISEV | Minimal Information for Studies of Extracellular Vesicles |
| CGRP | Calcitonin Gene-Related Peptide |
| RCTs | Randomized Controlled Trials |
| GPI | Glycosylphosphatidylinositol |
| EV-LPS/EV-Endotoxin | Lipopolysaccharide Present on EVs |
| HVPC | High-Voltage Pulsed Current |
| IL-6, IL-8, IL-10 | Interleukin-6/-8/-10 |
| LAL | Limulus Amebocyte Lysate (Endotoxin Assay) |
| LPS | Lipopolysaccharide |
| MMP−9 | Matrix Metalloproteinase−9 |
| NTA | Nanoparticle Tracking Analysis |
| POSAS | Patient And Observer Scar Assessment Scale |
| VAS (Pain VAS) | Visual Analog Scale For Pain |